Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Multi-omics profiling of the gut Microbiota–Metabolism–Immunity axis reveals predictive biomarkers of treatment response and survival in diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2025-3533

Published: 2025

Journal Articles

Efficacy and safety observation of luspatercept for refractory anemia associated with hematologic malignanciesluspatercept治疗血液系统恶性肿瘤相关难治性贫血的疗效和安全性观察luspatercept 改善与血液系统恶性肿瘤相关的难治性贫血的疗效和安全性：一项观察

Ping Zhang, Shuling Yu, Shengfa Gao, Huiling Zhu, Shanhao Tang, Yongcheng Sun, Binbin Lai, Xiao Wu, Lieguang Chen, Kaihong Xu, Lixia Sheng, Guifang Ouyang

Blood (2025) 146 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2025-2888

Published: 2025

Journal Articles

Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study

Chen Mei, Guifang Ouyang, Yanjuan Lin, Min Zhang, Minming Li, Hongyan Tong

Blood (2025) 146 (Supplement 1): 492.

https://doi.org/10.1182/blood-2025-492

Published: 2025

Journal Articles

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 91.

https://doi.org/10.1182/blood-2025-91

Published: 2025

Journal Articles

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Lixia Sheng, Wen Lei, Duo Wu, Yi Zhang, Yanli Lai, Shuyan Wang, Duobing Zou, Ping Zhang, Kaihong Xu, Shanhao Tang, Huijie Hu, Tongyu Li, Qitian Mu, Xiaofei Ye, Hui Liu, Wenbin Qian, Guifang Ouyang

Blood (2025) 146 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2025-1929

Published: 2025

Journal Articles

Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study

Lixia Sheng, Yanli Lai, Sheng Nie, Yuning Pan, Di Wang, Shanhao Tang, Kaihong Xu, Yongcheng Sun, Ping Zhang, Binbin Lai, Lieguang Chen, Guifang Ouyang

Blood (2025) 146 (Supplement 1): 59.

https://doi.org/10.1182/blood-2025-59

Published: 2025

Journal Articles

Low-dose chidamide maintenance therapy following allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia or lymphoma: A phase 2, open-label, multicenter, single-arm trial

Yi Yu, Weihao Chen, Jimin Shi, Yi Luo, Jian Yu, Huarui Fu, Xiaoyu Lai, Lizhen Liu, Guifang Ouyang, He Huang, Lixia Sheng, Weijie Cao, Yanmin Zhao

Blood (2025) 146 (Supplement 1): 169.

https://doi.org/10.1182/blood-2025-169

Published: 2025

Journal Articles

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Jiefeng Tong, Songfu Jiang, Qian Luo, Shanhu Qian, Guifang Ouyang, Yanli Lai, Huifang Jiang, Yuxia Jiang, Hui Zeng, Baodong Ye, Wei Jiang, Wenbin Qian

Blood (2024) 144 (Supplement 1): 7762.

https://doi.org/10.1182/blood-2024-204522

Published: 2024

Journal Articles

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2024-212040

Published: 2024

Journal Articles

Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Keshu Zhou, Hongyun Xing, Qingliang Teng, Wuping Li, Yafei Wang, Feng Zhu, Zhengming Jin, Li Zhiming, Guifang Ouyang, Fang Xu, Shihua Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 4627.

https://doi.org/10.1182/blood-2024-202814

Published: 2024

Journal Articles

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 663.

https://doi.org/10.1182/blood-2024-200433

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

A Prospective, Multicenter, Single-Arm Study on the Combination of Orelabrutinib and Rituximab in the Second-Line Treatment of Relapsed/Refractory Marginal Zone Lymphoma

Guifang Ouyang, Lixia Sheng, Jiaping Wang, Hui Zeng, Shanhao Tang, Xibin Xiao, Yamin Tan, Qunyi Guo, Yanping Shao, Minchao Yan, Wenbin Qian

Blood (2024) 144 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2024-198485

Published: 2024

Journal Articles

Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring

Lixia Sheng, Guifang Ouyang, Yanli Lai, Sheng Nie, Di Wang, Shanhao Tang, Yuning Pan, Kaihong Xu, Yongcheng Sun, Ping Zhang, Binbin Lai, Lieguang Chen

Blood (2024) 144 (Supplement 1): 4500.

https://doi.org/10.1182/blood-2024-198355

Published: 2024

Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2023-179073

Published: 2023

Journal Articles

The Correlation between Alterations in the Intestinal Microbiome and Early Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B-Cell Lymphoma

Lixia Sheng, Jiaping WANG, Zhouning Lin, Yanli Lai, Guifang Ouyang

Blood (2023) 142 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2023-186700

Published: 2023

Journal Articles

IPSS-M Predicts Survival Outcomes Significantly Better Than IPSS-R in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasms

Blood (2023) 142 (Supplement 1): 3579.

https://doi.org/10.1182/blood-2023-189068

Published: 2023

Journal Articles

Comparison of Long-Term Outcome between Imatinib and Dasatinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia-a Multi-Center Retrospective Study

Fangshu Guan, Luxin Yang, Panpan Zhu, Xiaoyu Lai, Lizhen Liu, Jimin Shi, Yanmin Zhao, Jian Yu, Huarui Fu, Yi Zhao, Jianping Lan, Yi Chen, Ying Lu, Guifang Ouyang, Yang Xu, Xi Qiu, Zhen Cai, He Huang, Yi Luo

Blood (2023) 142 (Supplement 1): 7056.

https://doi.org/10.1182/blood-2023-184478

Published: 2023

Journal Articles

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Blood (2023) 142 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2023-184433

Published: 2023

Journal Articles

Impact of TP53 Allelic State on Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasm

Blood (2023) 142 (Supplement 1): 2228.

https://doi.org/10.1182/blood-2023-184668

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Multi-omics profiling of the gut Microbiota–Metabolism–Immunity axis reveals predictive biomarkers of treatment response and survival in diffuse large B-cell lymphoma

Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study

Low-dose chidamide maintenance therapy following allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia or lymphoma: A phase 2, open-label, multicenter, single-arm trial

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

A Prospective, Multicenter, Single-Arm Study on the Combination of Orelabrutinib and Rituximab in the Second-Line Treatment of Relapsed/Refractory Marginal Zone Lymphoma

Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

The Correlation between Alterations in the Intestinal Microbiome and Early Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B-Cell Lymphoma

IPSS-M Predicts Survival Outcomes Significantly Better Than IPSS-R in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasms

Comparison of Long-Term Outcome between Imatinib and Dasatinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia-a Multi-Center Retrospective Study

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Impact of TP53 Allelic State on Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only